Skip to main content

Table 2 Cox proportional hazards models of mortality in patients with AE-SAID-ILD (n = 25)

From: Frequency, proportion of PF-ILD, and prognostic factors in patients with acute exacerbation of ILD related to systemic autoimmune diseases

Variable

Hazard ratio

95% CI

p value

lower

upper

Age, y

1.019

0.956

1.089

0.565

Sex, male

1.323

0.429

4.897

0.637

Smoking, never vs. former/current

0.851

0.191

2.789

0.805

Pack-years of smoking

1.011

0.992

1.030

0.250

SAID, RA vs. non-RA

2.127

0.648

9.514

0.225

Duration from SAID-diagnosis to AE, months

1.000

0.994

1.005

0.931

Duration from ILD-diagnosis to AE, months

1.005

0.996

1.014

0.279

ILD preceding SAID, + 

1.521

0.458

4.580

0.472

Data before AE a

 FVC before AE, % pred

0.988

0.950

1.025

0.511

 DLCO before AE, % pred

0.980

0.908

1.046

0.545

 HRCT pattern before AE, UIP vs. non-UIP

0.774

0.241

2.481

0.659

 JRS severity grade before AE, 3/4 vs.1/2

10.97

1.535

219.6

0.016

 GAP staging system before AE, 2/3 vs. 1

5.705

0.931

43.88

0.059

 Preceding immunosuppressive treatments for SAID, + 

4.066

0.798

74.14

0.101

 Preceding oxygen therapy, + 

2.071

0.461

6.857

0.305

 PF-ILD, + 

1.817

0.489

5.650

0.345

Data at AE

 P/F ratio at AE

0.994

0.986

1.003

0.208

 Extent scores on HRCT at AE (full score 25)

1.120

0.972

1.322

0.120

 HRCT pattern at AE, diffuse vs. non-diffuse

4.040

0.782

73.92

0.106

 Peripheral blood WBC at AE, high (vs. low)

6.350

1.682

41.34

0.005

 Peripheral blood Neutrophil at AE, high (vs. low)

13.27

2.447

246.2

0.001

 Serum CRP at AE, mg/dL

1.002

0.999

1.005

0.218

 Serum LDH at AE, U/L

1.002

0.999

1.005

0.240

 Serum KL-6 at AE, U/mL

1.000

0.999

1.001

0.994

 Serum S100A8 at AE, high (vs. low)

2.243

0.590

10.65

0.239

 Treatments for AE within 3 days, + 

0.435

0.141

1.609

0.194

 Addition of immunosuppressants for AE, + 

1.023

0.340

3.180

0.968

 Treatment with PMX-DHP for AE, + 

0.749

0.203

2.305

0.625

 Treatment with PMX-DHP for AE within 3 days, + 

0.105

0.005

0.858

0.035

 Serum CRP 2 days after starting treatments for AE, mg/dL

1.086

0.999

1.169

0.051

 Serum LDH 2 days after starting treatments for AE, U/L

1.005

1.001

1.008

0.006

  1. Abbreviations: AE Acute exacerbation, SAID-ILD Systemic autoimmune disease-related interstitial lung disease, RA Rheumatoid arthritis, FVC Forced vital capacity, DLCO Diffusion lung capacity for carbon monoxide, UIP Usual interstitial pneumonia, HRCT High-resolution computed tomography, JRS Japanese Respiratory Society, GAP Gender, age, and physiology, PF-ILD Progressive fibrotic interstitial lung disease, WBC White blood cells, Neut Neutrophils, CRP C-reactive protein, LDH Lactate dehydrogenase, KL-6 Krebs von den Lungen-6, SP-D Surfactant protein D, P/F PaO2/FiO, PMX-DHP Direct haemoperfusion with a polymyxin B-immobilised fibre column
  2. a Pulmonary function tests and severity scores were evaluated within 12 months before AE-SAID-ILD
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us